1. A <scp>neuromuscular‐based</scp> analysis of the open payments program
- Author
-
Sanjeeva Onteddu, Yohei Harada, Carolina Gil Tommee, Vaishali Thombre, Karthika Veerapaneni, Amarnath Annapureddy, Sisira Yadala, Songthip T. Ounpraseuth, Masahisa Katsuno, Nidhi Kapoor, Mudassar Kamran, Madhu Jasti, Krishna Nalleballe, Sen Sheng, and Sukanthi Kovvuru
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Time Factors ,Databases, Factual ,Physiology ,media_common.quotation_subject ,030105 genetics & heredity ,Medicare ,Eteplirsen ,Centers for Medicare and Medicaid Services, U.S ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Physicians ,Physiology (medical) ,Humans ,Medicine ,Neurologists ,health care economics and organizations ,media_common ,Health economics ,business.industry ,Payment ,United States ,Emergency medicine ,Nusinersen ,Neurology (clinical) ,business ,Medicaid ,030217 neurology & neurosurgery - Abstract
Introduction In August 2013, the Centers for Medicare and Medicaid Services (CMS) Open Payments Program (OPP) made eligible payment information publicly available. Data about industry payments to neuromuscular neurologists are lacking. Method Financial relationships were investigated between industry and US neuromuscular neurologists from January 2014 through December 2018 using the CMS OPP database. Results The total annual payments increased more than 6-fold during the study period. The top 10% of physician-beneficiaries collected 80% to 90% of total industry payments except in 2014. In 2018, the most common drugs associated with payments to neuromuscular neurologists were nusinersen, vortioxetine, eteplirsen, alglucosidase alpha, edaravone, and intravenous immunoglobulin. Discussion A substantial increase in the annual payments to neuromuscular physicians during the study period is likely due to the development of new treatments, including gene therapy.
- Published
- 2020